Researchers find HPV vaccination provides long-term protection

Vaccination against the high-risk human papilloma virus (HPV) in 16 and 18 year-old teenage girls offers long-lasting protection

Many countries routinely vaccinate teenage girls against human papilloma virus (HPV) infection. New research published in Deutsches Ärzteblatt International
[1]
suggests that vaccination against the high-risk HPV types 16 and 18 offers long-lasting protection.

Analysis of 10 randomised controlled trials, involving 46,436 participants, found that vaccination prevented 83% of infections in trials with a short duration of follow-up (median 3 years) and 94% of infections in trials with a long duration of follow-up (median 6 years). Efficacy of vaccination against persistent HPV infection was 90% with short follow-up and 95% with long follow-up.

“Long-term observation does not indicate any loss of antiviral protection after vaccination,” write Yvonne Deleré, from the Robert Koch Institute Berlin, and co-authors.

References

 

[1] Deleré Y, Wichmann O, Klug SJ et al. The efficacy and duration of vaccine protection against human papillomavirus—a systematic review and meta-analysis. Dtsch Arztebl Int 2014;111:584–591.

 

Last updated
Citation
The Pharmaceutical Journal, PJ, 11 October 2014, Vol 293, No 7831;293(7831):DOI:10.1211/PJ.2014.20066668